GPhA Files Amicus Brief in K-Dur Case

by McDonnell Boehnen Hulbert & Berghoff LLP
Contact

[author: Kevin E. Noonan]

Generic  Pharmaceutical Association (GPhA)The Generic Pharmaceutical Association (GPhA) filed an amicus brief in support of a grant of certiorari by the Supreme Court in the K-Dur case (In re K-Dur Antitrust Litigation).  Characterizing the issue as being "profoundly important to the pharmaceutical market and pharmaceutical companies," GPhA argues that "[t]he decision of the court of appeals directly threatens the ability of the generic pharmaceutical industry to ensure consumers affordable access to lifesaving and health-preserving medicines."  The Third Circuit's opinion was "novel and deeply disruptive," because "[c]onsumers benefit from early, definite resolution of Para. IV litigation" and such settlements have "brought enormous benefits to consumers by speeding the entry of generic drugs to the market."

GPhA's brief points out that "up to now," all circuit courts of appeal had agreed that reverse payment settlement agreements were lawful and "did not violate the antitrust laws, so long as the agreement did not restrain trade beyond the scope of the patent itself."  The Third Circuit, "[d]isagreeing with every other circuit to reach the question," held these agreements presumptively illegal as an antitrust violation, even when the agreement permits "the generic to enter the market before the brand-name company's patent expires and even when the agreement does not restrain trade beyond the scope of the patent."  Accordingly, the Supreme Court should rectify this situation; otherwise, settlements of ANDA litigation shall be inhibited and "an agreement that benefits consumers -- by providing them with earlier access to low-priced generic drugs than the brand-name patents would allow -- into a basis for treble damages liability under the antitrust laws."  The brief points out the paradox that left to stand, the Third Circuit's decision "will inevitably delay the entry of new generic drugs into the marketplace, with potentially devastating costs to consumers and the Nation.

Speaking on behalf of its membership, GPhA's brief contends that the "uncertain legal regime" will extend to "a host of business and litigation decisions that other circuits deem permissible," including not only "nationwide class actions" but also enforcement actions by the FTC (the brief notes that the Commission "has already vowed" to bring such actions").  This will "chill" efforts by generic drug companies that promote competition by bringing "cost-saving generic medicines to market."  Consequently, GPhA argues that the uncertainties created by the Third Circuit's decision must be resolved by the Court to permit new generic drug applications to be filed; unlike arguments that focus on the investment by the branded drug companies, GPhA argues that litigation costs are a significant contributor to the calculus of whether a generic drug company develops a generic version of a branded drug.  Uncertainty about the "legal regime" that governs ANDA litigation, particularly when it limits the ability to settle, will result in "fewer generic drug applications that would trigger a patent challenge will be filed," GPhA argues in its brief.  In view of the Third Circuit's decision, "a settlement of litigation that is permissible in several circuits may nonetheless lead to antitrust liability in the Third Circuit" and that uncertainty "will inevitably deter generic drug manufacturers from challenging patents to accelerate the entry of their products."  And this situation is not limited to the Third Circuit, because the antitrust laws permit an action to be filed "in any judicial district in the country" and plaintiffs can be expected to flock to district courts in that circuit.  In this regard GPhA makes the paradoxical argument that the K-Dur decision "gave insufficient weight to the patent rights at stake:  a patentee does not violate the antitrust laws by exercising its patent rights, whether by bringing a patent-infringement suit or by settling one."  And GPhA reminds the Court that the reverse payment settlement agreement at issue in the decision "has already been reviewed by two different courts of appeals, with extensive participation by the federal government as both a party and as amicus curiae" with decisions against (Third Circuit) and in favor (Eleventh Circuit) the permissibility of the agreement under the antitrust laws.  Accordingly:

This Court should not leave the national pharmaceutical market to be governed by the minority view of a single Third Circuit panel; it should step in now to resolve this crucially important conflict.

The brief accentuates the importance of the issues in this case to the pharmaceutical industry, branded and generic alike.  The Third Circuit's decision puts at risk a "multi-billion-dollar" industry based on a "minority rule" from this Circuit.  The brief supports the importance of the Court granting certiorari and (presumptively) overturning the Third Circuit's decision by recounting (at length) the cost savings generic drugs provide to the public and the provisions of the Hatch-Waxman Act that impose litigation costs prior to market entry (which, presumably, would otherwise provide profits to fund ANDA litigation), saying that "[t]he ability to litigate is the ["extremely high"] price of admission" to the marketplace.  While acknowledging that Hatch-Waxman provides for ANDA litigation, "nothing in either the Hatch-Waxman Act or the antitrust laws mandates that every single patent lawsuit under Paragraph IV must be fought to the bitter end."  The brief reminds the Court (as have the parties and other amici) that settlement is "generally permissible" in antitrust litigation, citing Standard Oil Co. (Ind.) v. United States, 283 U.S. 163, 171 (1931).  And the brief notes that the Hatch-Waxman Act specifically provides for FDA approval of a generic company's ANDA upon settlement (21 U.S.C.§ 355(j)(5)(B)(iii)(I),(II)).  Indeed, the Act itself does not distinguish between judgment and settlement as ways to terminate ANDA litigation, and Congress did not require branded and generic companies to "litigate to the death" (a requirement that would provide the branded drug company with an advantage because branded companies, not generics, are making profits in the marketplace that can be used to fund ANDA litigation).  Settlements benefit consumers, GPhA argues, because ANDA litigation provides the "chief obstacle[]" to market entry of generic drugs.  Thus, "settlements are a key way of overcoming those obstacles and bringing cheaper pharmaceuticals to market sooner [including "earlier or better access to the market"]" which is the reason for the ANDA provisions of the Act.

The brief also maintains that its arguments are supported by actual industry experience over the "past several years," where "hundreds of patent settlements" have "brought a low-cost generic drug into the marketplace sooner than the brand-name drug's patent would have permitted" (impliedly contrasting these actual data with the economic hypotheses promulgated by the FTC).  Examples include Lipitor® and tamoxifen, noting that Barr was able to bring a generic version of tamoxifen to market nine years before patent expiry while three other generic companies failed to prevail in separate ANDA litigation.  "If Barr had instead litigated to final judgment and lost as the other companies did, the brand-name manufacturer would have faced no generic competition for nine more years," the brief notes.  And even ignoring these benefits, GPhA argues that the money not spent on ANDA litigation can be (better) spent "developing and bringing to market a new generic drug" and conversely that limiting settlements consigns these monies to litigation at the expense of new generic drug development.

The brief also (expressly) echoes party (and generic company) Upsher's brief regarding the extent and nature of the circuit split created by the Third Circuit's decision, extending to a disagreement over exactly the same settlement agreement previously found lawful by the Eleventh Circuit.  In addition, the brief notes the overlap between plaintiffs, defendants, agreements and amici (including the FTC) in these several disputes.  While circumstances in earlier cases may have not support certiorari, "the case for [the] Court's review has become incontrovertible," the brief argues.  And should the Court delay in deciding to resolve these disparate legal standards, GPhA asserts that the only consequence would be "gamesmanship and forum shopping" (in some instances by the FTC itself).  Given the concentration of pharmaceutical companies in the Third Circuit, the K-Dur decision affects the "epicenter of Paragraph IV litigation" and (for that reason alone) merits review, according to the brief.  The likelihood for such a concentration of antitrust challenges to ANDA litigation reverse payment settlement agreements is not merely a prediction but relies on statements from the FTC Chairman Jon Leibowitz that the Commission intends to file challenges to reverse payment settlement agreements in district courts in the Third Circuit "for years to come."  "Percolation" of the issue, to the extent it might otherwise occur, "may well have come to an end" in view of the Third Circuit's decision.

Getting to the heart of the matter, the brief ends with an argument that the Third Circuit's decision was simply wrong:

Patents restrict competition for a specified time, but they are not unlawful restraints of trade.  Rather, they represent a determination by Congress that the incentive to innovate justifies granting "Inventors the exclusive Right to their . . . Discoveries" for a "limited Time[]."  U.S. Const. art. I, § 8, cl. 8.  The court of appeals concluded that the rule of law applied in its sister circuits must be wrong because no antitrust plaintiff has yet prevailed under it.  See Pet. App. 32a-33a ("[N]o court applying the scope of the patent test has ever permitted a reverse payment antitrust case to go to trial.").  But the reason why plaintiffs do not prevail under that rule is simply that they have not stated an unlawful restraint on competition:  a patentee has a statutory right to exclude its competitors from the market, or to license its patent to competitors if it wishes.  Where, as here, the agreement does not restrain any trade beyond the scope of the patent, there simply cannot be an antitrust violation.

In a statement released to the press, Ralph G. Neas, President and CEO of the GPhA said:

Simply put, the Third Circuit erred in its conclusion that the presumption of validity of a patent is not a substantive right of the patent holder.  All other circuits that have ruled have held that patent settlements are presumptively valid.  The Third Circuit ruling is an outlier.

This case could determine how an entire industry does business, because it would dramatically affect the economics of each decision to introduce a new generic drug.  The current industry paradigm of challenging patents on branded drugs in order to bring new generics to market as soon as possible has produced $1.06 trillion in savings over the past 10 years.

The facts are clear.  Patent settlements save.  They are pro competition, pro-consumer and have saved consumers and taxpayers billions of dollars.

For additional information regarding this topic, please see:

• "Bayer Files Amicus Brief in K-Dur Case," September 27, 2012
• "PhRMA Files Amicus Brief in K-Dur Case," September 26, 2012
• "Generic Defendant Petitions for Certiorari in K-Dur Litigation," September 16, 2012
• "Merck Asks Supreme Court to Review Third Circuit K–Dur Decision," August 28, 2012
• "The Federal Trade Commission Finally Wins One," July 18, 2012

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP
Contact
more
less

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.